Nanofiber Scaffolds as Drug Delivery Systems to Bridge Spinal Cord Injury

Faccendini, Angela; Vigani, Barbara; Rossi, Silvia; Sandri, Giuseppina; Bonferoni, Maria Cristina; Caramella, Carla; Ferrari, Franca

doi:10.3390/ph10030063

Cited by 40 publications

(21 citation statements)

References 168 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have shown graphene to have great potential as a bioscaffold at the site of the lesion in chronic SCI allowing for neuronal regeneration [ 4 , 54 , 55 , 56 , 57 , 58 , 59 , 60 ]. GO nanocomposite is considered to be a favorable material for use in treatment because of its unique electro-physico-chemical properties and it is conductivity.…”

Section: Selected Biomaterials That Hold Promise For Future Clinicmentioning

confidence: 99%

“…Abbreviations used: IL-1α: Interleukin 1α; IL-1β: Interleukin 1β; IL-6: Interleukin 6; TNF-α: Tumor Necrosis Factor α. Figure reprinted with permission from “Nanofiber Scaffolds as Drug Delivery Systems to Bridge Spinal Cord Injury” by Faccendini et al, Pharmaceuticals 2017, 10, 63, licensed under a Creative Commons Attribution license [ 4 ].…”

Section: Figurementioning

confidence: 99%

See 1 more Smart Citation

Translational Regenerative Therapies for Chronic Spinal Cord Injury

Dalamagkas

Tsintou

Seifalian

et al. 2018

IJMS

View full text Add to dashboard Cite

Spinal cord injury is a chronic and debilitating neurological condition that is currently being managed symptomatically with no real therapeutic strategies available. Even though there is no consensus on the best time to start interventions, the chronic phase is definitely the most stable target in order to determine whether a therapy can effectively restore neurological function. The advancements of nanoscience and stem cell technology, combined with the powerful, novel neuroimaging modalities that have arisen can now accelerate the path of promising novel therapeutic strategies from bench to bedside. Several types of stem cells have reached up to clinical trials phase II, including adult neural stem cells, human spinal cord stem cells, olfactory ensheathing cells, autologous Schwann cells, umbilical cord blood-derived mononuclear cells, adult mesenchymal cells, and autologous bone-marrow-derived stem cells. There also have been combinations of different molecular therapies; these have been either alone or combined with supportive scaffolds with nanostructures to facilitate favorable cell–material interactions. The results already show promise but it will take some coordinated actions in order to develop a proper step-by-step approach to solve impactful problems with neural repair.

show abstract

Section: Selected Biomaterials That Hold Promise For Future Clinicmentioning

confidence: 99%

Section: Figurementioning

confidence: 99%

Translational Regenerative Therapies for Chronic Spinal Cord Injury

Dalamagkas

Tsintou

Seifalian

et al. 2018

IJMS

View full text Add to dashboard Cite

show abstract

“…A burst release of the VPA in the first 6 h was observed, which comprised around 80% of the encapsulated substance ( Figure 3). The burst effect is functional for the treatment of primary SCI, contributing to the reduction of the cascade of secondary events and attenuation of a specific cellular response (4). Moreover, the core-shell fibers present a thinner sheath layer and the porous structure of the fiber surface may allow for higher water adsorption and for more drug molecules to diffuse out of the core into the surrounding media (24).…”

Section: Discussionmentioning

confidence: 99%

“…This lesion damages axonal pathways, interrupting synaptic transmission between the brain and spinal cord and subsequently altering motor, sensory, and autonomic functions below the level of injury (3). The complex pathophysiology of SCI may explain the current lack of an effective therapeutic approach for the regeneration of damaged neuronal cells and the recovery of motor function (4).…”

Section: Introductionmentioning

confidence: 99%

VPA/PLGA microfibers produced by coaxial electrospinning for the treatment of central nervous system injury

Reis

Sperling

Teixeira

et al. 2020

Braz J Med Biol Res

View full text Add to dashboard Cite

The central nervous system shows limited regenerative capacity after injury. Spinal cord injury (SCI) is a devastating traumatic injury resulting in loss of sensory, motor, and autonomic function distal from the level of injury. An appropriate combination of biomaterials and bioactive substances is currently thought to be a promising approach to treat this condition. Systemic administration of valproic acid (VPA) has been previously shown to promote functional recovery in animal models of SCI. In this study, VPA was encapsulated in poly(lactic-co-glycolic acid) (PLGA) microfibers by the coaxial electrospinning technique. Fibers showed continuous and cylindrical morphology, randomly oriented fibers, and compatible morphological and mechanical characteristics for application in SCI. Drug-release analysis indicated a rapid release of VPA during the first day of the in vitro test. The coaxial fibers containing VPA supported adhesion, viability, and proliferation of PC12 cells. In addition, the VPA/PLGA microfibers induced the reduction of PC12 cell viability, as has already been described in the literature. The biomaterials were implanted in rats after SCI. The groups that received the implants did not show increased functional recovery or tissue regeneration compared to the control. These results indicated the cytocompatibility of the VPA/PLGA core-shell microfibers and that it may be a promising approach to treat SCI when combined with other strategies.

show abstract

“…Nowadays, the development of therapeutic platforms, with both neuroprotective and neuroregenerative potential, able to guarantee a controlled drug delivery, as well as the neurite outgrowth at the site of injury, represents a current challenge in the biomedical and pharmaceutical fields. In the context of SCI, polymer-based fibers, produced by the electrospinning technique, are considered both as attractive bridging materials, filling the gap in the spinal cord [39][40][41][42], and as effective drug delivery systems, thanks to their high area/volume ratio that maximize the cellular uptake of the drug released [40,43].…”

Section: Introductionmentioning

confidence: 99%

Dual-Functioning Scaffolds for the Treatment of Spinal Cord Injury: Alginate Nanofibers Loaded with the Sigma 1 Receptor (S1R) Agonist RC-33 in Chitosan Films

et al. 2019

Self Cite

View full text Add to dashboard Cite

The present work proposed a novel therapeutic platform with both neuroprotective and neuroregenerative potential to be used in the treatment of spinal cord injury (SCI). A dual-functioning scaffold for the delivery of the neuroprotective S1R agonist, RC-33, to be locally implanted at the site of SCI, was developed. RC-33-loaded fibers, containing alginate (ALG) and a mixture of two different grades of poly(ethylene oxide) (PEO), were prepared by electrospinning. After ionotropic cross-linking, fibers were incorporated in chitosan (CS) films to obtain a drug delivery system more flexible, easier to handle, and characterized by a controlled degradation rate. Dialysis equilibrium studies demonstrated that ALG was able to form an interaction product with the cationic RC-33 and to control RC-33 release in the physiological medium. Fibers loaded with RC-33 at the concentration corresponding to 10% of ALG maximum binding capacity were incorporated in films based on CS at two different molecular weights—low (CSL) and medium (CSM)—solubilized in acetic (AA) or glutamic (GA) acid. CSL- based scaffolds were subjected to a degradation test in order to investigate if the different CSL salification could affect the film behavior when in contact with media that mimic SCI environment. CSL AA exhibited a slower biodegradation and a good compatibility towards human neuroblastoma cell line.

show abstract

Nanofiber Scaffolds as Drug Delivery Systems to Bridge Spinal Cord Injury

Cited by 40 publications

References 168 publications

Translational Regenerative Therapies for Chronic Spinal Cord Injury

Translational Regenerative Therapies for Chronic Spinal Cord Injury

VPA/PLGA microfibers produced by coaxial electrospinning for the treatment of central nervous system injury

Dual-Functioning Scaffolds for the Treatment of Spinal Cord Injury: Alginate Nanofibers Loaded with the Sigma 1 Receptor (S1R) Agonist RC-33 in Chitosan Films

Contact Info

Product

Resources

About